Effects of age on the detection and management of breast cancer

Andrew McGuire, James A L Brown, Carmel Malone, Ray McLaughlin, Michael J Kerin, Andrew McGuire, James A L Brown, Carmel Malone, Ray McLaughlin, Michael J Kerin

Abstract

Currently, breast cancer affects approximately 12% of women worldwide. While the incidence of breast cancer rises with age, a younger age at diagnosis is linked to increased mortality. We discuss age related factors affecting breast cancer diagnosis, management and treatment, exploring key concepts and identifying critical areas requiring further research. We examine age as a factor in breast cancer diagnosis and treatment relating it to factors such as genetic status, breast cancer subtype, hormone factors and nodal status. We examine the effects of age as seen through the adoption of population wide breast cancer screening programs. Assessing the incidence rates of each breast cancer subtype, in the context of age, we examine the observed correlations. We explore how age affects patient's prognosis, exploring the effects of age on stage and subtype incidence. Finally we discuss the future of breast cancer diagnosis and treatment, examining the potential of emerging tests and technologies (such as microRNA) and how novel research findings are being translated into clinically relevant practices.

Keywords: age; breast cancer; miRNA; screening; subtype.

Figures

Figure 1
Figure 1
Overview of current breast cancer screening practices.
Figure 2
Figure 2
Family history, breast cancer risk and screening.
Figure 3
Figure 3
Metastatic breast cancer sites by age group.

References

    1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61:69–90. doi: 10.3322/caac.20107.
    1. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics. CA Cancer J. Clin. 2011;61:409–418. doi: 10.3322/caac.20134.
    1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J. Clin. 2014;64:9–29. doi: 10.3322/caac.21208.
    1. Yancik R. Cancer burden in the aged: An epidemiologic and demographic overview. Cancer. 1997;80:1273–1283. doi: 10.1002/(SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>;2-4.
    1. International Cancer Screening Network. [(accessed on 10 May 2015)]; Available online:
    1. Paap E., Verbeek A.L., Botterweck A.A., van Doorne-Nagtegaal H.J., Imhof-Tas M., de Koning H.J., Otto S.J., de Munck L., van der Steen A., Holland R., et al. Breast cancer screening halves the risk of breast cancer death: A case-referent study. Breast. 2014;23:439–444. doi: 10.1016/j.breast.2014.03.002.
    1. Warner E., Plewes D.B., Hill K.A., Causer P.A., Zubovits J.T., Jong R.A., Cutrara M.R., DeBoer G., Yaffe M.J., Messner S.J., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–1325. doi: 10.1001/jama.292.11.1317.
    1. Gotzsche P.C., Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 2006 doi: 10.1002/14651858,CD001877.pub2.
    1. Blanch J., Sala M., Roman M., Ederra M., Salas D., Zubizarreta R., Sanchez M., Rue M., Castells X. Cumulative risk of cancer detection in breast cancer screening by protocol strategy. Breast Cancer Res. Treat. 2013;138:869–877. doi: 10.1007/s10549-013-2458-5.
    1. Nelson H.D., Tyne K., Naik A., Bougatsos C., Chan B.K., Humphrey L. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2009 doi: 10.1059/0003-4819-151-10-200911170-00009.
    1. Humphrey L.L., Helfand M., Chan B.K., Woolf S.H. Breast cancer screening: A summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2002;137:347–360.
    1. Nystrom L., Andersson I., Bjurstam N., Frisell J., Nordenskjold B., Rutqvist L.E. Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet. 2002;359:909–919. doi: 10.1016/S0140-6736(02)08020-0.
    1. Kosters J.P., Gotzsche P.C. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst. Rev. 2003 doi: 10.1002/14651858.CD003373.
    1. US Preventive Services Task Force Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2009 doi: 10.7326/0003-4819-151-10-200911170-00008.
    1. Spencer D.B., Potter J.E., Chung M.A., Fulton J., Hebert W., Cady B. Mammographic screening and disease presentation of breast cancer patients who die of disease. Breast J. 2004;10:298–303. doi: 10.1111/j.1075-122X.2004.21461.x.
    1. Webb M.L., Cady B., Michaelson J.S., Bush D.M., Calvillo K.Z., Kopans D.B., Smith B.L. A failure analysis of invasive breast cancer: Most deaths from disease occur in women not regularly screened. Cancer. 2014;120:2839–2846. doi: 10.1002/cncr.28199.
    1. Autier P., Boniol M., Gavin A., Vatten L.J. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ. 2011 doi: 10.1136/bmj.d4411.
    1. Kalager M., Zelen M., Langmark F., Adami H.O. Effect of screening mammography on breast-cancer mortality in Norway. N. Engl. J. Med. 2010;363:1203–1210. doi: 10.1056/NEJMoa1000727.
    1. Jorgensen K.J., Zahl P.H., Gotzsche P.C. Breast cancer mortality in organised mammography screening in Denmark: Comparative study. BMJ. 2010 doi: 10.1136/bmj.c1241.
    1. Vacek P.M., Skelly J.M. A prospective study of the use and effects of screening mammography in women aged 70 and older. J. Am. Geriatr. Soc. 2015;63:1–7. doi: 10.1111/jgs.13184.
    1. Nelson H.D., Tyne K., Naik A., Bougatsos C., Chan B.K., Humphrey L. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2009 doi: 10.1059/0003-4819-151-10-200911170-00009.
    1. Gøtzsche P.C., Jørgensen K.J. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 2013 doi: 10.1002/14651858.CD001877.pub5.
    1. Rosenberg R.D., Hunt W.C., Williamson M.R., Gilliland F.D., Wiest P.W., Kelsey C.A., Key C.R., Linver M.N. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology. 1998;209:511–518. doi: 10.1148/radiology.209.2.9807581.
    1. Kerlikowske K., Grady D., Barclay J., Sickles E.A., Ernster V. Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA. 1996;276:39–43.
    1. Carney P.A., Miglioretti D.L., Yankaskas B.C., Kerlikowske K., Rosenberg R., Rutter C.M., Geller B.M., Abraham L.A., Taplin S.H., Dignan M., et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann. Intern. Med. 2003;138:168–175. doi: 10.7326/0003-4819-138-3-200302040-00008.
    1. Lei J., Yang P., Zhang L., Wang Y., Yang K. Diagnostic accuracy of digital breast tomosynthesis versus digital mammography for benign and malignant lesions in breasts: A meta-analysis. Eur. Radiol. 2014;24:595–602. doi: 10.1007/s00330-013-3012-x.
    1. Jochelson M.S., Dershaw D.D., Sung J.S., Heerdt A.S., Thornton C., Moskowitz C.S., Ferrara J., Morris E.A. Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology. 2013;266:743–751. doi: 10.1148/radiol.12121084.
    1. Kelly K.M., Richwald G.A. Automated whole-breast ultrasound: Advancing the performance of breast cancer screening. Semin. Ultrasound CT MR. 2011;32:273–280. doi: 10.1053/j.sult.2011.02.004.
    1. Hubbard R.A., Kerlikowske K., Flowers C.I., Yankaskas B.C., Zhu W., Miglioretti D.L. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: A cohort study. Ann. Intern. Med. 2011;155:481–492. doi: 10.7326/0003-4819-155-8-201110180-00004.
    1. Leach M.O., Boggis C.R., Dixon A.K., Easton D.F., Eeles R.A., Evans D.G., Gilbert F.J., Griebsch I., Hoff R.J., Kessar P., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) Lancet. 2005;365:1769–1778. doi: 10.1016/S0140-6736(05)66646-9.
    1. Kriege M., Brekelmans C.T., Boetes C., Besnard P.E., Zonderland H.M., Obdeijn I.M., Manoliu R.A., Kok T., Peterse H., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med. 2004;351:427–437. doi: 10.1056/NEJMoa031759.
    1. Le-Petross H.T., Whitman G.J., Atchley D.P., Yuan Y., Gutierrez-Barrera A., Hortobagyi G.N., Litton J.K., Arun B.K. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011;117:3900–3907. doi: 10.1002/cncr.25971.
    1. Saslow D., Boetes C., Burke W., Harms S., Leach M.O., Lehman C.D., Morris E., Pisano E., Schnall M., Sener S., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 2007;57:75–89. doi: 10.3322/canjclin.57.2.75.
    1. Saadatmand S., Tilanus-Linthorst M.M., Rutgers E.J., Hoogerbrugge N., Oosterwijk J.C., Tollenaar R.A., Hooning M., Loo C.E., Obdeijn I.M., Heijnsdijk E.A., et al. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J. Natl. Cancer Inst. 2013;105:1314–1321. doi: 10.1093/jnci/djt203.
    1. Berg W.A., Zhang Z., Lehrer D., Jong R.A., Pisano E.D., Barr R.G., Bohm-Velez M., Mahoney M.C., Evans W.P., 3rd, Larsen L.H., et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307:1394–1404. doi: 10.1001/jama.2012.388.
    1. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1998;62:676–689. doi: 10.1086/301749.
    1. Nelson H.D., Huffman L.H., Fu R., Harris E.L. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2005;143:362–379. doi: 10.7326/0003-4819-143-5-200509060-00012.
    1. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA. 2003;100:8418–8423. doi: 10.1073/pnas.0932692100.
    1. Shiovitz S., Korde L.A. Genetics of Breast Cancer: A Topic in Evolution. Ann. Oncol. 2015 doi: 10.1093/annonc/mdv022.
    1. Warner E.T., Colditz G.A., Palmer J.R., Partridge A.H., Rosner B.A., Tamimi R.M. Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: Are there differences before and after age 40? Breast Cancer Res. Treat. 2013;142:165–175. doi: 10.1007/s10549-013-2721-9.
    1. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Jr., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 1999;341:2061–2067. doi: 10.1056/NEJM199912303412706.
    1. Scher K.S., Hurria A. Under-representation of older adults in cancer registration trials: Known problem, little progress. J. Clin. Oncol. 2012;30:2036–2038. doi: 10.1200/JCO.2012.41.6727.
    1. Joyce K.M., McInerney N.M., Waters P.S., Sweeney K.J., Barry K., Kerin M.J. Symptomatic breast cancer diagnosis and multimodal management in women aged 40 to 50 years; consequences of current mammographic screening programs. Clin. Breast Cancer. 2014;15:e125–e130. doi: 10.1016/j.clbc.2014.11.001.
    1. Mao Y., Chen X., Gao W., Liu J., Shen K. Treatment patterns and affecting factors in breast cancer patients over 65-years of age. Zhonghua Zhong Liu Za Zhi. 2014;36:366–371.
    1. Land L.H., Dalton S.O., Jorgensen T.L., Ewertz M. Comorbidity and survival after early breast cancer. A review. Crit. Rev. Oncol. Hematol. 2012;81:196–205. doi: 10.1016/j.critrevonc.2011.03.001.
    1. Barthelemy P., Heitz D., Mathelin C., Polesi H., Asmane I., Litique V., Rob L., Bergerat J.P., Kurtz J.E. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit. Rev. Oncol. Hematol. 2011;79:196–204. doi: 10.1016/j.critrevonc.2010.06.005.
    1. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093.
    1. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes—Dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011;22:1736–1747. doi: 10.1093/annonc/mdr304.
    1. Eroles P., Bosch A., Perez-Fidalgo J.A., Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38:698–707. doi: 10.1016/j.ctrv.2011.11.005.
    1. Sweeney C., Bernard P.S., Factor R.E., Kwan M.L., Habel L.A., Quesenberry C.P., Jr., Shakespear K., Weltzien E.K., Stijleman I.J., Davis C.A., et al. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: Differences by age, race, and tumor characteristics. Cancer Epidemiol. Biomarkers Prev. 2014;23:714–724. doi: 10.1158/1055-9965.EPI-13-1023.
    1. Calza S., Hall P., Auer G., Bjohle J., Klaar S., Kronenwett U., Liu E.T., Miller L., Ploner A., Smeds J., et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006 doi: 10.1186/bcr1517.
    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63:11–30. doi: 10.3322/caac.21166.
    1. Yankaskas B.C. Epidemiology of breast cancer in young women. Breast Dis. 2005;23:3–8.
    1. Kurian A.W., Fish K., Shema S.J., Clarke C.A. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010 doi: 10.1186/bcr2780.
    1. United Kingdom Office for National Statistics . Cancer Survival in England: Patients Diagnosed 2007–2011 and Followed Up to 2012. United Kingdom Office for National Statistics; Newport, UK: 2013.
    1. Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am. J. Hum. Genet. 1995;57:1457–1462.
    1. Honrado E., Benitez J., Palacios J. The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod. Pathol. 2005;18:1305–1320. doi: 10.1038/modpathol.3800453.
    1. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
    1. Foulkes W.D., Stefansson I.M., Chappuis P.O., Begin L.R., Goffin J.R., Wong N., Trudel M., Akslen L.A. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 2003;95:1482–1485. doi: 10.1093/jnci/djg050.
    1. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71. doi: 10.1126/science.7545954.
    1. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792. doi: 10.1038/378789a0.
    1. Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D., et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 1996;12:333–337. doi: 10.1038/ng0396-333.
    1. Narod S.A., Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer. 2004;4:665–676. doi: 10.1038/nrc1431.
    1. Easton D.F. How many more breast cancer predisposition genes are there? Breast Cancer Res. 1999;1:14–17. doi: 10.1186/bcr6.
    1. Campeau P.M., Foulkes W.D., Tischkowitz M.D. Hereditary breast cancer: New genetic developments, new therapeutic avenues. Hum. Genet. 2008;124:31–42. doi: 10.1007/s00439-008-0529-1.
    1. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25:1329–1333. doi: 10.1200/JCO.2006.09.1066.
    1. Lubinski J., Huzarski T., Byrski T., Lynch H.T., Cybulski C., Ghadirian P., Stawicka M., Foulkes W.D., Kilar E., Kim-Sing C., et al. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int. J. Cancer. 2012;131:229–234. doi: 10.1002/ijc.26369.
    1. Evans D.G., Lalloo F., Wallace A., Rahman N. Update on the manchester scoring system for BRCA1 and BRCA2 testing. J. Med. Genet. 2005 doi: 10.1136/jmg.2005.031989.
    1. Evans D.G., Baildam A.D., Anderson E., Brain A., Shenton A., Vasen H.F., Eccles D., Lucassen A., Pichert G., Hamed H., et al. Risk reducing mastectomy: Outcomes in 10 European centres. J. Med. Genet. 2009;46:254–258. doi: 10.1136/jmg.2008.062232.
    1. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C., Garber J.E., Neuhausen S.L., Matloff E., Eeles R., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–975. doi: 10.1001/jama.2010.1237.
    1. Moyer V.A. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2014;160:271–281.
    1. US Preventive Services Task Force Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Ann. Intern. Med. 2005;143:355–361.
    1. Esquela-Kerscher A., Slack F.J. Oncomirs—MicroRNAs with a role in cancer. Nat. Rev. Cancer. 2006;6:259–269. doi: 10.1038/nrc1840.
    1. Mathieu J., Ruohola-Baker H. Regulation of stem cell populations by microRNAs. Adv. Exp. Med. Biol. 2013;786:329–351.
    1. He L., Hannon G.J. MicroRNAs: Small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004;5:522–531. doi: 10.1038/nrg1379.
    1. Christodoulatos G.S., Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World J. Clin. Oncol. 2014;5:71–81. doi: 10.5306/wjco.v5.i2.71.
    1. Simon L.M., Edelstein L.C., Nagalla S., Woodley A.B., Chen E.S., Kong X., Ma L., Fortina P., Kunapuli S., Holinstat M., et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood. 2014;123:e37–e45. doi: 10.1182/blood-2013-12-544692.
    1. Noren Hooten N., Abdelmohsen K., Gorospe M., Ejiogu N., Zonderman A.B., Evans M.K. MicroRNA expression patterns reveal differential expression of target genes with age. PLoS ONE. 2010;5:e10724. doi: 10.1371/journal.pone.0010724.
    1. Liang R., Bates D.J., Wang E. Epigenetic Control of MicroRNA Expression and Aging. Curr. Genomics. 2009;10:184–193. doi: 10.2174/138920209788185225.
    1. Serpico D., Molino L., di Cosimo S. MicroRNAs in breast cancer development and treatment. Cancer Treat Rev. 2014;40:595–604. doi: 10.1016/j.ctrv.2013.11.002.
    1. Heneghan H.M., Miller N., Kelly R., Newell J., Kerin M.J. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010;15:673–682. doi: 10.1634/theoncologist.2010-0103.
    1. McDermott A.M., Miller N., Wall D., Martyn L.M., Ball G., Sweeney K.J., Kerin M.J. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS ONE. 2014;9:e87032. doi: 10.1371/journal.pone.0087032.
    1. Dai X., Chen A., Bai Z. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. Sci. Rep. 2014 doi: 10.1038/srep06566.
    1. Hatse S., Brouwers B., Dalmasso B., Laenen A., Kenis C., Schoffski P., Wildiers H. Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: Correlation with chronological age but not with fitness/frailty status. PLoS ONE. 2014;9:e110644. doi: 10.1371/journal.pone.0110644.
    1. Jenkins E.O., Deal A.M., Anders C.K., Prat A., Perou C.M., Carey L.A., Muss H.B. Age-specific changes in intrinsic breast cancer subtypes: A focus on older women. Oncologist. 2014;19:1076–1083. doi: 10.1634/theoncologist.2014-0184.
    1. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502. doi: 10.1001/jama.295.21.2492.
    1. O’Brien K.M., Cole S.R., Tse C.K., Perou C.M., Carey L.A., Foulkes W.D., Dressler L.G., Geradts J., Millikan R.C. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin. Cancer Res. 2010;16:6100–6110. doi: 10.1158/1078-0432.CCR-10-1533.
    1. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 2010;28:1684–1691. doi: 10.1200/JCO.2009.24.9284.
    1. Nguyen P.L., Taghian A.G., Katz M.S., Niemierko A., Raad R.F.A., Boon W.L., Bellon J.R., Wong J.S., Smith B.L., Harris J.R. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 2008;26:2373–2378. doi: 10.1200/JCO.2007.14.4287.
    1. Turkoz F.P., Solak M., Petekkaya I., Keskin O., Kertmen N., Sarici F., Arik Z., Babacan T., Ozisik Y., Altundag K. Association between common risk factors and molecular subtypes in breast cancer patients. Breast. 2013;22:344–350. doi: 10.1016/j.breast.2012.08.005.
    1. Anderson K.N., Schwab R.B., Martinez M.E. Reproductive risk factors and breast cancer subtypes: A review of the literature. Breast Cancer Res. Treat. 2014;144:1–10. doi: 10.1007/s10549-014-2852-7.
    1. Early Breast Cancer Trialists’ Collaborative Group Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998;351:1451–1467.
    1. Love R.R., Barden H.S., Mazess R.B., Epstein S., Chappell R.J. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch. Intern. Med. 1994;154:2585–2588. doi: 10.1001/archinte.1994.00420220081009.
    1. Cutuli B., Petit J., Fricker J., Jung G., Schumacher C., Velten M., Abecassis J. Adjuvant tamoxifen in breast-cancer-treatment in postmenopausal women—Occurrence of thromboembolic complications. Oncol. Rep. 1994;1:59–63.
    1. Meier C.R., Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br. J. Clin. Pharmacol. 1998;45:608–612. doi: 10.1046/j.1365-2125.1998.00733.x.
    1. Geisler J., King N., Dowsett M., Ottestad L., Lundgren S., Walton P., Kormeset P.O., Lonning P.E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer. 1996;74:1286–1291. doi: 10.1038/bjc.1996.531.
    1. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 2003;348:2431–2442. doi: 10.1056/NEJMra023246.
    1. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., Forbes J.F. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135–1141. doi: 10.1016/S1470-2045(10)70257-6.
    1. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet. 2002;359:2131–2139. doi: 10.1016/S0140-6736(02)09088-8.
    1. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005;353:2747–2757. doi: 10.1056/NEJMoa052258.
    1. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 2005;97:1262–1271. doi: 10.1093/jnci/dji250.
    1. Jakesz R., Greil R., Gnant M., Schmid M., Kwasny W., Kubista E., Mlineritsch B., Tausch C., Stierer M., Hofbauer F., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6A. J. Natl. Cancer Inst. 2007;99:1845–1853. doi: 10.1093/jnci/djm246.
    1. Burstein H.J., Temin S., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., Giordano S.H., Hudis C.A., Rowden D., Solky A.J., et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J. Clin. Oncol. 2014;32:2255–2269. doi: 10.1200/JCO.2013.54.2258.
    1. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007;13:2329–2334. doi: 10.1158/1078-0432.CCR-06-1109.
    1. Eiermann W., Rezai M., Kummel S., Kuhn T., Warm M., Friedrichs K., Schneeweiss A., Markmann S., Eggemann H., Hilfrich J., et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann. Oncol. 2013;24:618–624. doi: 10.1093/annonc/mds512.
    1. Dobbe E., Gurney K., Kiekow S., Lafferty J.S., Kolesar J.M. Gene-expression assays: New tools to individualize treatment of early-stage breast cancer. Am. J. Health Syst. Pharm. 2008;65:23–28. doi: 10.2146/ajhp060352.
    1. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., Ravdin P., Bugarini R., Baehner F.L., Davidson N.E., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65. doi: 10.1016/S1470-2045(09)70314-6.
    1. Albert J.M., Gonzalez-Angulo A.M., Guray M., Sahin A., Strom E.A., Tereffe W., Woodward W.A., Tucker S.L., Hunt K.K., Hortobagyi G.N., et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010;77:1296–1302. doi: 10.1016/j.ijrobp.2009.12.011.
    1. Kim H.J., Han W., Yi O.V., Shin H.C., Ahn S.K., Koh B.S., Moon H.G., You J.H., Son B.H., Ahn S.H., et al. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Res. Treat. 2011;130:499–505. doi: 10.1007/s10549-011-1736-3.
    1. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001;344:783–792. doi: 10.1056/NEJM200103153441101.
    1. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Jr., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005;353:1673–1684. doi: 10.1056/NEJMoa052122.
    1. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005;353:1659–1672. doi: 10.1056/NEJMoa052306.
    1. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., Pusztai L., Green M.C., Arun B.K., Giordano S.H., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 2005;23:3676–3685. doi: 10.1200/JCO.2005.07.032.
    1. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.A., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32. doi: 10.1016/S1470-2045(11)70336-9.
    1. Greenup R., Buchanan A., Lorizio W., Rhoads K., Chan S., Leedom T., King R., McLennan J., Crawford B., Marcom P.K., et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann. Surg. Oncol. 2013;20:3254–3258. doi: 10.1245/s10434-013-3205-1.
    1. Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., Lanchbury J.S., Stemke-Hale K., Hennessy B.T., Arun B.K., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin. Cancer Res. 2011;17:1082–1089. doi: 10.1158/1078-0432.CCR-10-2560.
    1. Robertson L., Hanson H., Seal S., Warren-Perry M., Hughes D., Howell I., Turnbull C., Houlston R., Shanley S., Butler S., et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br. J. Cancer. 2012;106:1234–1238. doi: 10.1038/bjc.2012.31.
    1. Theriault R.L., Carlson R.W., Allred C., Anderson B.O., Burstein H.J., Edge S.B., Farrar W.B., Forero A., Giordano S.H., Goldstein L.J., et al. Breast cancer, version 3.2013: Featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Netw. 2013;11:753–760.
    1. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., Veer L.V., Garber J.E., Evans G.R., Narod S.A., Isaacs C., Matloff E., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J. Clin. Oncol. 2004;22:1055–1062. doi: 10.1200/JCO.2004.04.188.
    1. Ernst M.F., van de Poll-Franse L.V., Roukema J.A., Coebergh J.W., van Gestel C.M., Vreugdenhil G., Louwman M.J., Voogd A.C. Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast. 2007;16:344–351. doi: 10.1016/j.breast.2007.01.001.
    1. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R., Jeong J.H., Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med. 2002;347:1233–1241. doi: 10.1056/NEJMoa022152.
    1. Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A., Aguilar M., Marubini E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 2002;347:1227–1232. doi: 10.1056/NEJMoa020989.
    1. Jones H.A., Antonini N., Hart A.A., Peterse J.L., Horiot J.C., Collin F., Poortmans P.M., Oei S.B., Collette L., Struikmans H., et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial. J. Clin. Oncol. 2009;27:4939–4947. doi: 10.1200/JCO.2008.21.5764.
    1. Botteri E., Bagnardi V., Rotmensz N., Gentilini O., Disalvatore D., Bazolli B., Luini A., Veronesi U. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann. Oncol. 2010;21:723–728. doi: 10.1093/annonc/mdp386.
    1. Mahmood U., Morris C., Neuner G., Koshy M., Kesmodel S., Buras R., Chumsri S., Bao T., Tkaczuk K., Feigenberg S. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer. 2004;100:688–693. doi: 10.1002/cncr.20022.
    1. Mahmood U., Morris C., Neuner G., Koshy M., Kesmodel S., Buras R., Chumsri S., Bao T., Tkaczuk K., Feigenberg S. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012;83:1387–1393. doi: 10.1016/j.ijrobp.2011.10.075.
    1. Veronesi U., Salvadori B., Luini A., Greco M., Saccozzi R., del Vecchio M., Mariani L., Zurrida S., Rilke F. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1973 patients. Eur. J. Cancer. 1995;31A:1574–1579. doi: 10.1016/0959-8049(95)00271-J.
    1. Jobsen J.J., van der Palen J., Ong F., Meerwaldt J.H. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int. J. Radiat. Oncol. Biol. Phys. 2003;57:724–731. doi: 10.1016/S0360-3016(03)00644-8.
    1. Bartelink H., Horiot J.C., Poortmans P.M., Struikmans H., van den Bogaert W., Fourquet A., Jager J.J., Hoogenraad W.J., Oei S.B., Warlam-Rodenhuis C.C., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J. Clin. Oncol. 2007;25:3259–3265. doi: 10.1200/JCO.2007.11.4991.
    1. Hughes K.S., Schnaper L.A., Bellon J.R., Cirrincione C.T., Berry D.A., McCormick B., Muss H.B., Smith B.L., Hudis C.A., Winer E.P., et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J. Clin. Oncol. 2013;31:2382–2387. doi: 10.1200/JCO.2012.45.2615.
    1. Early Breast Cancer Trialists Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717.
    1. Partridge A.H., Gelber S., Piccart-Gebhart M.J., Focant F., Scullion M., Holmes E., Winer E.P., Gelber R.D. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: Results from a herceptin adjuvant trial. J. Clin. Oncol. 2013;31:2692–2698. doi: 10.1200/JCO.2012.44.1956.
    1. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., Theriault R.L., Singh G., Binkley S.M., Sneige N., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 1999;17:460–469.
    1. Grassadonia A., di Nicola M., Grossi S., Noccioli P., Tavoletta S., Politi R., Angelucci D., Marinelli C., Zilli M., Cefaro G.A., et al. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. Ann. Surg. Oncol. 2014;21:1575–1582. doi: 10.1245/s10434-014-3535-7.
    1. Cataliotti L., Buzdar A.U., Noguchi S., Bines J., Takatsuka Y., Petrakova K., Dube P., de Oliveira C.T. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106:2095–2103. doi: 10.1002/cncr.21872.
    1. Colleoni M., Rotmensz N., Peruzzotti G., Maisonneuve P., Orlando L., Ghisini R., Viale G., Pruneri G., Veronesi P., Luini A., et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann. Oncol. 2006;17:1497–1503. doi: 10.1093/annonc/mdl145.
    1. Han W., Kim S.W., Park I.A., Kang D., Youn Y.K., Oh S.K., Choe K.J., Noh D.Y. Young age: An independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer. 2004;4:82. doi: 10.1186/1471-2407-4-82.
    1. De la Rochefordiere A., Asselain B., Campana F., Scholl S.M., Fenton J., Vilcoq J.R., Durand J.C., Pouillart P., Magdelenat H., Fourquet A. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993;341:1039–1043. doi: 10.1016/0140-6736(93)92407-K.
    1. Kim K., Chie E.K., Han W., Noh D.Y., Oh D.Y., Im S.A., Kim T.Y., Bang Y.J., Ha S.W. Age <40 years is an independent prognostic factor predicting inferior overall survival in patients treated with breast conservative therapy. Breast J. 2011;17:75–78.
    1. Gajdos C., Tartter P.I., Bleiweiss I.J., Bodian C., Brower S.T. Stage 0 to stage III breast cancer in young women. J. Am. Coll. Surg. 2000;190:523–529. doi: 10.1016/S1072-7515(00)00257-X.
    1. Cancello G., Maisonneuve P., Rotmensz N., Viale G., Mastropasqua M.G., Pruneri G., Veronesi P., Torrisi R., Montagna E., Luini A., et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann. Oncol. 2010;21:1974–1981.
    1. Han W., Kang S.Y. Relationship between age at diagnosis and outcome of premenopausal breast cancer: Age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res. Treat. 2010;119:193–200. doi: 10.1007/s10549-009-0388-z.
    1. Bharat A., Aft R.L., Gao F., Margenthaler J.A. Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J. Surg. Oncol. 2009;100:248–251. doi: 10.1002/jso.21268.
    1. Inwald E.C., Klinkhammer-Schalke M., Hofstadter F., Zeman F., Koller M., Gerstenhauer M., Ortmann O. Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. Breast Cancer Res. Treat. 2013;139:539–552. doi: 10.1007/s10549-013-2560-8.
    1. Colleoni M., Rotmensz N., Robertson C., Orlando L., Viale G., Renne G., Luini A., Veronesi P., Intra M., Orecchia R., et al. Very young women (<35 years) with operable breast cancer: Features of disease at presentation. Ann. Oncol. 2002;13:273–279.
    1. Choi D.H., Kim S., Rimm D.L., Carter D., Haffty B.G. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J. 2005;11:404–411. doi: 10.1097/00130404-200509000-00008.
    1. Kheirelseid E.H., Boggs J.M., Curran C., Glynn R.W., Dooley C., Sweeney K.J., Kerin M.J. Younger age as a prognostic indicator in breast cancer: A cohort study. BMC Cancer. 2011 doi: 10.1186/1471-2407-11-383.
    1. Alieldin N.H., Abo-Elazm O.M., Bilal D., Salem S.E., Gouda E., Elmongy M., Ibrahim A.S. Age at diagnosis in women with non-metastatic breast cancer: Is it related to prognosis? J. Egypt Natl. Cancer Inst. 2014;26:23–30. doi: 10.1016/j.jnci.2013.08.005.
    1. Hwang E.S., Lichtensztajn D.Y., Gomez S.L., Fowble B., Clarke C.A. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status. Cancer. 2013;119:1402–1411. doi: 10.1002/cncr.27795.
    1. Diab S.G., Elledge R.M., Clark G.M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl. Cancer Inst. 2000;92:550–556. doi: 10.1093/jnci/92.7.550.
    1. Land L.H., Dalton S.O., Jensen M.B., Ewertz M. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br. J. Cancer. 2012;107:1901–1907. doi: 10.1038/bjc.2012.472.
    1. Diederichs C., Berger K., Bartels D.B. The measurement of multiple chronic diseases—A systematic review on existing multimorbidity indices. J. Gerontol. A Biol. Sci. Med. Sci. 2011;66:301–311. doi: 10.1093/gerona/glq208.
    1. Aaldriks A.A., Giltay E.J., le Cessie S., van der Geest L.G., Portielje J.E., Tanis B.C., Nortier J.W., Maartense E. Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy. Breast. 2013;22:753–760. doi: 10.1016/j.breast.2013.01.011.
    1. Hamaker M.E., Seynaeve C., Wymenga A.N., van Tinteren H., Nortier J.W.R., Maartense E., de Graaf H., de Jongh F.E., Braun J.J., Los M., et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch breast cancer trialists’ group. Breast. 2014;23:81–87. doi: 10.1016/j.breast.2013.11.004.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться